...
首页> 外文期刊>Journal of cellular and molecular medicine. >Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?
【24h】

Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?

机译:早期诊断阿尔茨海默氏病的生物标志物:“ ALZheimer关联基因”-一种新的血液生物标志物?

获取原文
获取原文并翻译 | 示例
           

摘要

Simple, non-invasive tests for an early detection of degenerative dementia by use of biomarkers are urgently required. However, up to the present, no validated extracerebral diagnostic markers (plasma/serum, platelets, urine, connective tissue) for the early diagnosis of Alzheimer disease (AD) are available. In disease stages with evident cognitive disturbances, the clinical diagnosis of probable AD is made with around 90% accuracy using modern clinical, neuropsychological and imaging methods. Diagnostic sensitivity and specificity even in early disease stages are improved by CSF markers, in particular combined tau and amyloid beta peptides (Abeta) and plasma markers (eg, Abeta-42/Abeta-40 ratio). Recently, a novel gene/protein--ALZAS (Alzheimer Associated Protein)--with a 79 amino acid sequence, containing the amyloid beta-42 fragment (Abeta-42), the amyloid precursor protein (APP) transmembrane signal and a 12 amino acid C-terminal, not present in any other known APP alleles, has been discovered on chromosome 21 within the APP region. Reverse transcriptase-PCR revealed the expression of the transcript of this protein in the cortex and hippocampal regions as well as in lymphocytes of human AD patients. The expression of ALZAS is mirrored by a specific autoimmune response in AD patients, directed against the ct-12 end of the ALZAS-peptide but not against the Abeta-sequence. ELISA studies of plasma detected highest titers of ALZAS in patients with mild cognitive impairment (presymptomatic AD), but only moderately increased titers in autopsy-confirmed AD, whereas low or undetectable ct-12 titers were found in cognitively intact age-matched subjects and young controls. The antigen, ALZAS protein, was detected in plasma in later clinical stages of AD. It is suggested that ALZAS represents an indicator in a dynamic equilibrium between both peripheral and brain degenerative changes in AD and may become a useful "non-invasive" diagnostic marker via a simple blood test.
机译:迫切需要通过生物标志物早期检测退行性痴呆的简单,非侵入性测试。但是,到目前为止,尚无用于早期诊断阿尔茨海默病(AD)的经过验证的脑外诊断标志物(血浆/血清,血小板,尿液,结缔组织)。在具有明显认知障碍的疾病阶段,使用现代临床,神经心理学和影像学方法对可能的AD进行临床诊断的准确率约为90%。 CSF标记物,尤其是tau和淀粉样β肽(Abeta)和血浆标记物(例如,Abeta-42 / Abeta-40比率)的结合,甚至可以提高疾病早期诊断的敏感性和特异性。最近,一种具有79个氨基酸序列的新型基因/蛋白质-ALZAS(阿尔茨海默症相关蛋白),包含淀粉样β-42片段(Abeta-42),淀粉样前体蛋白(APP)跨膜信号和12个氨基酸在APP区域内的第21号染色体上发现了不存在于任何其他已知APP等位基因中的酸性C末端。逆转录-PCR显示该蛋白的转录本在人AD患者的皮质和海马区以及淋巴细胞中表达。 ALZAS的表达反映在AD患者中,是针对ALZAS肽ct-12末端而不针对Abeta序列的特异性自身免疫反应。血浆的ELISA研究在轻度认知功能障碍(有症状的AD)患者中检测到最高的ALZAS滴度,但在尸检确认的AD中滴度仅适度增加,而在认知完好的年龄匹配的受试者和年轻人中发现的ct-12滴度较低或无法检测到。控制。在AD的晚期临床血浆中检测到抗原ALZAS蛋白。建议ALZAS代表AD周围和大脑退行性变化之间动态平衡的指标,并可能通过简单的血液检查成为有用的“非侵入性”诊断标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号